These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29643249)

  • 41. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.
    Bradley T; Fera D; Bhiman J; Eslamizar L; Lu X; Anasti K; Zhang R; Sutherland LL; Scearce RM; Bowman CM; Stolarchuk C; Lloyd KE; Parks R; Eaton A; Foulger A; Nie X; Karim SSA; Barnett S; Kelsoe G; Kepler TB; Alam SM; Montefiori DC; Moody MA; Liao HX; Morris L; Santra S; Harrison SC; Haynes BF
    Cell Rep; 2016 Jan; 14(1):43-54. PubMed ID: 26725118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.
    Pauthner M; Havenar-Daughton C; Sok D; Nkolola JP; Bastidas R; Boopathy AV; Carnathan DG; Chandrashekar A; Cirelli KM; Cottrell CA; Eroshkin AM; Guenaga J; Kaushik K; Kulp DW; Liu J; McCoy LE; Oom AL; Ozorowski G; Post KW; Sharma SK; Steichen JM; de Taeye SW; Tokatlian T; Torrents de la Peña A; Butera ST; LaBranche CC; Montefiori DC; Silvestri G; Wilson IA; Irvine DJ; Sanders RW; Schief WR; Ward AB; Wyatt RT; Barouch DH; Crotty S; Burton DR
    Immunity; 2017 Jun; 46(6):1073-1088.e6. PubMed ID: 28636956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.
    Ditse Z; Mkhize NN; Yin M; Keefer M; Montefiori DC; Tomaras GD; Churchyard G; Mayer KH; Karuna S; Morgan C; Bekker LG; Mlisana K; Gray G; Moodie Z; Gilbert P; Moore PL; Williamson C; Morris L
    mSphere; 2020 Jan; 5(1):. PubMed ID: 31996422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
    Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design.
    Rantalainen K; Berndsen ZT; Murrell S; Cao L; Omorodion O; Torres JL; Wu M; Umotoy J; Copps J; Poignard P; Landais E; Paulson JC; Wilson IA; Ward AB
    Cell Rep; 2018 Jun; 23(11):3249-3261. PubMed ID: 29898396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
    Spearman P; Lally MA; Elizaga M; Montefiori D; Tomaras GD; McElrath MJ; Hural J; De Rosa SC; Sato A; Huang Y; Frey SE; Sato P; Donnelly J; Barnett S; Corey LJ;
    J Infect Dis; 2011 Apr; 203(8):1165-73. PubMed ID: 21451004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
    Heyndrickx L; Stewart-Jones G; Jansson M; Schuitemaker H; Bowles E; Buonaguro L; Grevstad B; Vinner L; Vereecken K; Parker J; Ramaswamy M; Biswas P; Vanham G; Scarlatti G; Fomsgaard A;
    PLoS One; 2013; 8(9):e74552. PubMed ID: 24023951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
    Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
    Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines.
    Zang Y; Du D; Li N; Su W; Liu X; Zhang Y; Nie J; Wang Y; Kong W; Jiang C
    Vaccine; 2015 Jul; 33(32):3859-64. PubMed ID: 26126669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
    Khattar SK; Samal S; LaBranche CC; Montefiori DC; Collins PL; Samal SK
    PLoS One; 2013; 8(10):e78521. PubMed ID: 24098600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A novel immunization strategy to induce strong humoral responses against HIV-1 using combined DNA, recombinant vaccinia virus and protein vaccines].
    Liu C; Wang SH; Ren L; Hao YL; Zhang QC; Liu Y
    Bing Du Xue Bao; 2014 Nov; 30(6):645-51. PubMed ID: 25868279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.
    Godot V; Tcherakian C; Gil L; Cervera-Marzal I; Li G; Cheng L; Ortonne N; Lelièvre JD; Pantaleo G; Fenwick C; Centlivre M; Mouquet H; Cardinaud S; Zurawski SM; Zurawski G; Milpied P; Su L; Lévy Y
    PLoS Pathog; 2020 Nov; 16(11):e1009025. PubMed ID: 33253297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.
    Khattar SK; DeVico AL; LaBranche CC; Panda A; Montefiori DC; Samal SK
    J Virol; 2016 Feb; 90(3):1682-6. PubMed ID: 26581986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.
    Pissani F; Malherbe DC; Robins H; DeFilippis VR; Park B; Sellhorn G; Stamatatos L; Overbaugh J; Haigwood NL
    Vaccine; 2012 Aug; 30(37):5519-26. PubMed ID: 22749601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
    Saunders KO; Verkoczy LK; Jiang C; Zhang J; Parks R; Chen H; Housman M; Bouton-Verville H; Shen X; Trama AM; Scearce R; Sutherland L; Santra S; Newman A; Eaton A; Xu K; Georgiev IS; Joyce MG; Tomaras GD; Bonsignori M; Reed SG; Salazar A; Mascola JR; Moody MA; Cain DW; Centlivre M; Zurawski S; Zurawski G; Erickson HP; Kwong PD; Alam SM; Levy Y; Montefiori DC; Haynes BF
    Cell Rep; 2017 Dec; 21(13):3681-3690. PubMed ID: 29281818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.